Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TD-0212 TFA is an orally active dual pharmacology antagonist of angiotensin II type 1 receptor (AT1) and inhibitor of neprilysin (NEP)(pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 2,720.00 | |
50 mg | 10-14 weeks | $ 3,580.00 | |
100 mg | 10-14 weeks | $ 4,900.00 |
Description | TD-0212 TFA is an orally active dual pharmacology antagonist of angiotensin II type 1 receptor (AT1) and inhibitor of neprilysin (NEP)(pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP). |
Targets&IC50 | AT1:(pKi)8.9 , NEP:9.2(pIC50) |
In vitro | TD-0212 provides the enhanced activity of dual AT1/NEP inhibition and may have a lower risk of angioedema than dual ACE/NEP inhibition. |
In vivo | In renin-dependent and non-dependent hypertension models, TD-0212 can lower blood pressure, similar to omapatrilat and the combination of AT1 receptor antagonist and NEP inhibitor. |
Molecular Weight | 641.67 |
Formula | C30H35F4N3O6S |
CAS No. | 1073549-11-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (194.80 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TD-0212 TFA 1073549-11-7 Others TD0212 TFA TD 0212 TFA inhibitor inhibit